Адъюванты в ветеринарии и механизмы их действия

Адъюванты играют ключевую роль в современной ветеринарной вакцинологии, определяя эффективность вакцин для сельскохозяйственных животных. В контексте растущего спроса на экономически оптимальные и безопасные иммунопрепараты, понимание молекулярных основ действия адъювантов становится критически важным. Данный обзор охватывает пять основных типов адъювантов – минеральные (гидроксид и фосфат алюминия), масляные эмульсии, растительные сапонины, бактериальные компоненты (CpG, MPLA) и наноструктурированные системы (липосомы, PLGA, инулин) – и описывает их действие через пять ключевых механизмов: (1) усиление гуморального ответа (выработка нейтрализующих антител); (2) активацию клеточного иммунитета (дифференцировка Th1, генерация цитотоксических T‐лимфоцитов); (3) формирование депо антигена (пролонгированная стимуляция); (4) активацию врождённого иммунитета (распознавание паттернов, воспаление); (5) торможение избыточного воспаления. Анализируется видовая зависимость эффективности адъювантов, связанная с различиями в рецепторах врождённого иммунитета между видами животных. Обсуждаются побочные эффекты традиционных адъювантов (гранулёмы, системное воспаление, снижение продуктивности) и стратегии их минимизации. Выявлены новые направления развития – синтетические иммуномодуляторы, биоразлагаемые наночастицы и логически обоснованные комбинированные системы, обеспечивающие оптимальный иммунный ответ без развития нежелательных реакций. Полученные знания применяются в разработке более эффективных, безопасных и экономичных вакцин для профилактики инфекционных заболеваний сельскохозяйственных животных.

1. Хрипко О.П., Коновалов Д.И., Глущенко А.В., Алексеев А.Ю., Шестопалов М.А. Адъюванты для сельскохозяйственных животных: текущее состояние // Ветеринарный фармакологический вестник. 2025. Т. 33. N. 4. С. 54‐65. https://doi.org/10.65173/2541‐8203.2025.33.4.005

2. Sicard T., Kassardjian A., Julien J.P. B cell targeting by molecular adjuvants for enhanced immunogenicity. Expert Review of Vaccines, 2020, vol. 19, no. 11, pp. 1023‐1039. https://doi.org/10.1080/14760584.2020.1857736

3. Yao Y., Zhang Z., Yang Z. The combination of vaccines and adjuvants to prevent the occurrence of high incidence of infectious diseases in bovine. Frontiers in Veterinary Science, 2023, vol. 10, article number 1243835. https://doi.org/10.3389/fvets.2023.1243835

4. Zhao T., Cai Y., Jiang Y., He X., Wei Y., Yu Y., Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduction and Targeted Therapy, 2023, vol. 8, no. 1, article number 283. https://doi.org/10.1038/s41392‐023‐01557‐7

5. Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Frontiers in Immunology, 2017, vol. 8, article number 1547. https://doi.org/10.3389/fimmu.2017.01547

6. Stills H.F., Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR Journal, 2005, vol. 46, no. 3, pp. 280‐293. https://doi.org/10.1093/ilar.46.3.280

7. Ko E.J., Lee Y.T., Kim K.H., Jung Y.J., Lee Y., Denning T.L., Kang S.M. Effects of MF59 Adjuvant on Induction of Isotype‐Switched IgG Antibodies and Protection after Immunization with TDependent Influenza Virus Vaccine in the Absence of CD4+ T Cells. Journal of Virology, 2016, vol. 90, no. 15, pp. 6976‐6988. https://doi.org/10.1128/jvi.00339‐16

8. Moyer T.J., Kato Y., Abraham W., Chang J.Y.H., Kulp D.W., Watson N., Turner H.L., Menis S., Abbott R.K., Bhiman J.N., Melo M.B., Simon H.A., Herrera‐De la Mata S., Liang S., Seumois G., Agarwal Y., Li N., Burton D.R., Ward A.B., Schief W.R., Crotty S., Irvine D.J. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 2020, vol. 26, no. 3, pp. 430‐440. https://doi.org/10.1038/s41591‐020‐0753‐3

9. Csuka D., Simon D., Hobor R., Uray K., Prohaszka Z., Banlaki Z., Jani P.K., Szilagyi A., Hudecz F., Rajczy K., Beke G., Boros Major A., Tordai A., Illes Z., Berki T., Czirjak L., Fust G. Serum concentration of immunoglobulin G‐type antibodies against the whole Epstein‐Barr nuclear antigen 1 and its aa35‐58 or aa398‐404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clinical and Experimental Immunology, 2013, vol. 171, no. 3, pp. 255‐262. https://doi.org/10.1111/cei.12022

10. Pedersen G.K., Wørzner K., Andersen P., Christensen D. Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses. Frontiers in Immunology, 2020, vol. 11, article number 579761. https://doi.org/10.3389/fimmu.2020.579761

11. Spickler A.R., Roth J.A. Adjuvants in veterinary vaccines: modes of action and adverse effects. Journal of Veterinary Internal Medicine, 2003, vol. 17, no. 3, pp. 273‐281. https://doi.org/10.1111/j.1939‐1676.2003.tb02448.x

12. Dalsgaard K., Jensen M.H., Sorensen K.J. Saponin adjuvants. IV. Evaluation of the adjuvant quil A in the vaccination of cattle against foot‐and‐mouth disease. Acta Veterinaria Scandinavica, 1977, vol. 18, no. 3, pp. 349‐360. https://doi.org/10.1186/BF03548432

13. Stillman Z.S., Decker G.E., Dworzak M.R., Bloch E.D., Fromen C.A. Aluminum‐based metal‐organic framework nanoparticles as pulmonary vaccine adjuvants. Journal of Nanobiotechnology, 2023, vol. 21, no. 1, article number 39. https://doi.org/10.1186/s12951‐023‐01782‐w

14. Lin Y.L., Chow Y.H., Huang L.M., Hsieh S.M., Cheng P.Y., Hu K.C., Chiang B.L. A CpG‐adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2‐transgenic mice against lethal challenge. Scientific Reports, 2018, vol. 8, no. 1, article number 10713. https://doi.org/10.1038/s41598‐018‐28281‐5

15. Turley J.L., Lavelle E.C. Resolving adjuvant mode of action to enhance vaccine efficacy. Current Opinion in Immunology, 2022, vol. 77, article number 102229. https://doi.org/10.1016/j.coi.2022.102229

16. Kobayashi H., Horner A.A., Takabayashi K., Nguyen M.D., Huang E., Cinman N., Raz E. Immunostimulatory DNA pre‐priming: a novel approach for prolonged Th1‐biased immunity. Cellular Immunology, 1999, vol. 198, no. 1, pp. 69‐75. https://doi.org/10.1006/cimm.1999.1572

17. Eckl‐Dorna J., Batista F.D. BCR‐mediated uptake of antigen linked to TLR9 ligand stimulates B‐cell proliferation and antigenspecific plasma cell formation. Blood, 2009, vol. 113, no. 17, pp. 3969‐3977. https://doi.org/10.1182/blood‐2008‐10‐185421

18. Heegaard P.M., Dedieu L., Johnson N., Le Potier M.F., Mockey M., Mutinelli F., Vahlenkamp T., Vascellari M., Sørensen N.S. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Archives of Virology, 2011, vol. 156, no. 2, pp. 183‐202. https://doi.org/10.1007/s00705‐010‐0863‐1

19. Wilson‐Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. Journal of Pharmaceutical Sciences, 2009, vol. 98, no. 4, pp. 1278‐1316. https://doi.org/10.1002/jps.21523

20. Vogel F.R. Improving vaccine performance with adjuvants. Clinical Infectious Diseases, 2000, vol. 30 Suppl 3, no., pp. S266‐S270. https://doi.org/10.1086/313883

21. McNeela E.A., Mills K.H. Manipulating the immune system: humoral versus cell‐mediated immunity. Advanced Drug Delivery Reviews, 2001, vol. 51, no. 1‐3, pp. 43‐54. https://doi.org/10.1016/s0169‐409x(01)00169‐7

22. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology, 2002, vol. 20, no., pp. 709‐760. https://doi.org/10.1146/annurev.immunol.20.100301.064842

23. Verthelyi D., Ishii K.J., Gursel M., Takeshita F., Klinman D.M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. The Journal of Immunology, 2001, vol. 166, no. 4, pp. 2372‐2377. https://doi.org/10.4049/jimmunol.166.4.2372

24. Rolland‐Turner M., Farre G., Muller D., Rouet N., Boue F. Immunological tools for the assessment of both humoral and cellular immune responses in Foxes (Vulpes vulpes) using ovalbumin and cholera toxin B as an antigenic model. Vaccine, 2004, vol. 22, no. 31‐32, pp. 4163‐4172. https://doi.org/10.1016/j.vaccine.2004.06.050

25. Gershwin L.J., Behrens N.E., McEligot H.A., Carvallo‐Chaigneau F.R., Crum L.T., Gunnarson B.M., Corbeil L.B. A recombinant subunit vaccine for bovine RSV and Histophilus somni protects calves against dual pathogen challenge. Vaccine, 2017, vol. 35, no. 15, pp. 1954‐1963. https://doi.org/10.1016/j.vaccine.2017.01.059

26. Charerntantanakul W., Pongjaroenkit S. Co‐administration of saponin quil A and PRRSV‐1 modified‐live virus vaccine upregulates gene expression of type I interferon‐regulated gene, type I and II interferon, and inflammatory cytokines and reduces viremia in response to PRRSV‐2 challenge. Veterinary Immunology and Immunopathology, 2018, vol. 205, no., pp. 24‐34. https://doi.org/10.1016/j.vetimm.2018.10.005

27. Huis In 't Veld L.G., Cornelissen L.A., van den Bogaard L., Ansems M., Ho N.I., Adema G.J. Saponin‐based adjuvant uptake and induction of antigen cross‐presentation by CD11b+ dendritic cells and macrophages. NPJ Vaccines, 2025, vol. 10, no. 1, article number 15. https://doi.org/10.1038/s41541‐024‐01056‐y

28. Ho N.I., Huis In 't Veld L.G.M., Raaijmakers T.K., Adema G.J. Adjuvants Enhancing Cross‐Presentation by Dendritic Cells: The Key to More Effective Vaccines? Frontiers in Immunology, 2018, vol. 9, article number 2874. https://doi.org/10.3389/fimmu.2018.02874

29. Chen K., Wang N., Zhang X., Wang M., Liu Y., Shi Y. Potentials of saponins‐based adjuvants for nasal vaccines. Frontiers in Immunology, 2023, vol. 14, article number 1153042. https://doi.org/10.3389/fimmu.2023.1153042

30. Lorent J.H., Quetin‐Leclercq J., Mingeot‐Leclercq M.P. The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells. Organic and Biomolecular Chemistry, 2014, vol. 12, no. 44, pp. 8803‐8822. https://doi.org/10.1039/c4ob01652a

31. Lacaille‐Dubois M.A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS‐21: A review. Phytomedicine, 2019, vol. 60, article number 152905. https://doi.org/10.1016/j.phymed.2019.152905

32. Petrovsky N. Clinical development of SpikoGen®, an Advax‐CpG55.2 adjuvanted recombinant spike protein vaccine. Human Vaccines and Immunotherapeutics, 2024, vol. 20, no. 1, article number 2363016. https://doi.org/10.1080/21645515.2024.2363016

33. Lindblad E.B. Aluminium adjuvants – in retrospect and prospect. Vaccine, 2004, vol. 22, no. 27‐28, pp. 3658‐3668. https://doi.org/10.1016/j.vaccine.2004.03.032

34. Reed S.G., Tomai M., Gale M.J., Jr. New horizons in adjuvants for vaccine development. Current Opinion in Immunology, 2020, vol. 65, pp. 97‐101. https://doi.org/10.1016/j.coi.2020.08.008

35. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals, 1994, vol. 22, no. 1, pp. 53‐63. https://doi.org/10.1006/biol.1994.1008

36. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine, 2001, vol. 19, no. 17‐19, pp. 2666‐2672. https://doi.org/10.1016/s0264‐410x(00)00498‐9

37. Çokçalışkan C., Türkoğlu T., Sareyyüpoğlu B., Uzunlu E., Babak A., Özbilge B.B., Gülyaz V. QS‐21 enhances the early antibody response to oil adjuvant foot‐and‐mouth disease vaccine in cattle. Clinical and Experimental Vaccine Research, 2016, vol. 5, no. 2, pp. 138‐147. https://doi.org/10.7774/cevr.2016.5.2.138

38. Pulendran B., Arunachalam P.S., O'Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nature Reviews Drug Discovery, 2021, vol. 20, no. 6, pp. 454‐475. https://doi.org/10.1038/s41573‐021‐00163‐y

39. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds, in Vaccine Design. Pharmaceutical Biotechnology, ed. M. F. In: Powell, Newman, M.J. (eds), Springer, Boston, MA., 1995, vol. 6, pp. 229‐248.

40. Lan J., Feng D., He X., Zhang Q., Zhang R. Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines. Vaccines, 2024, vol. 12, no. 10, pp. 1187. https://doi.org/10.3390/vaccines12101187

41. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine, 2009, vol. 27, no. 25‐26, pp. 3331‐3334. https://doi.org/10.1016/j.vaccine.2009.01.084

42. Xing J., Zhao X., Li X., Fang R., Sun M., Zhang Y., Song N. The recent advances in vaccine adjuvants. Frontiers in Immunology, 2025, vol. 16, article number 1557415. https://doi.org/10.3389/fimmu.2025.1557415

43. Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology, Garland Science. New York, NY, USA, 2001. 600 p.

44. Choi J.H., You S.H., Ko M.K., Jo H.E., Shin S.H., Jo H., Lee M.J., Kim S.M., Kim B., Lee J.S., Park J.H. Improved immune responses and safety of foot‐and‐mouth disease vaccine containing immunostimulating components in pigs. Journal of Veterinary Science, 2020, vol. 21, no. 5, article number e74. https://doi.org/10.4142/jvs.2020.21.e74

45. Cloete M., Dungu B., Van Staden L.I., Ismail‐Cassim N., Vosloo W. Evaluation of different adjuvants for foot‐and‐mouth disease vaccine containing all the SAT serotypes. Onderstepoort Journal of Veterinary Research, 2008, vol. 75, no. 1, pp. 17‐31. https://doi.org/10.4102/ojvr.v75i1.84

46. Sandbulte M.R., Platt R., Roth J.A., Henningson J.N., Gibson K.A., Rajão D.S., Loving C.L., Vincent A.L. Divergent immune responses and disease outcomes in piglets immunized with inactivated and attenuated H3N2 swine influenza vaccines in the presence of maternally‐derived antibodies. Virology, 2014, vol. 464‐465, pp. 45‐54. https://doi.org/10.1016/j.virol.2014.06.027

47. Ling X., Dong Z., He J., Chen D., He D., Guo R., He Q., Li M. Advances in Polymer‐Based Self‐Adjuvanted Nanovaccines. Small, 2025, vol. 21, no. 16, article number e2409021. https://doi.org/10.1002/smll.202409021

48. Cassaidy B.J., Moser B.A., Solanki A., Chen Q., Shen J., Gotsis K., Lockhart Z., Rutledge N., Rosenberger M.G., Dong Y., Davis D., Esser‐Kahn A.P. Immune Potentiation of PLGA Controlled‐Release Vaccines for Improved Immunological Outcomes. ACS Omega, 2024, vol. 9, no. 10, pp. 11608‐11614. https://doi.org/10.1021/acsomega.3c06552

49. Comberlato A., Paloja K., Bastings M.M.C. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. Journal of Materials Chemistry B, 2019, vol. 7, no. 41, pp. 6321‐6346. https://doi.org/10.1039/c9tb01222b

50. Stanley A.C., Buxton D., Innes E.A., Huntley J.F. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cellmediated immunity in sheep. Vaccine, 2004, vol. 22, no. 29‐30, pp. 3929‐3941. https://doi.org/10.1016/j.vaccine.2004.04.022

51. Roth G.A., Picece V., Ou B.S., Luo W., Pulendran B., Appel E.A. Designing spatial and temporal control of vaccine responses. Nature Reviews Materials, 2022, vol. 7, no. 3, pp. 174‐195. https://doi.org/10.1038/s41578‐021‐00372‐2

52. Luo Q., Ahmed W., Dai Y., Mohsin A., Hang H., Zhuang Y., Guo M. Evaluation of a Virus‐like Nanoparticle Porcine Circovirus Type‐2 (PCV2) Capsid Protein Fused with the Pig Immunoglobulin Fc Fragment as a Novel Vaccine Candidate against PCV2 in Mice. Vaccines, 2021, vol. 9, no. 10, article number 1128. https://doi.org/10.3390/vaccines9101128

53. Facciolà A., Visalli G., Laganà A., Di Pietro A. An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines, 2022, vol. 10, no. 5, article number 819. https://doi.org/10.3390/vaccines10050819

54. Jeon D., Hill E., McNeel D.G. Toll‐like receptor agonists as cancer vaccine adjuvants. Human Vaccines and Immunotherapeutics, 2024, vol. 20, no. 1, article number 2297453. https://doi.org/10.1080/21645515.2023.2297453

55. Hop H.T., Simborio H.L., Reyes A.W.B., Arayan L.T., Min W., Lee H.J., Kim D.H., Chang H.H., Kim S. Immunogenicity and protective effect of recombinant Brucella abortus Ndk (rNdk) against a virulent strain B. abortus 544 infection in BALB/c mice. FEMS Microbiology Letters, 2015, vol. 362, no. 4, pp. 1‐6. https://doi.org/10.1093/femsle/fnv003

56. Nooraei S., Sarkar Lotfabadi A., Akbarzadehmoallemkolaei M., Rezaei N. Immunogenicity of Different Types of Adjuvants and Nano‐Adjuvants in Veterinary Vaccines: A Comprehensive Review. Vaccines, 2023, vol. 11, no. 2, pp. 453. https://doi.org/10.3390/vaccines11020453

57. Quandt D., Rothe K., Baerwald C., Rossol M. GPRC6A mediates Alum‐induced Nlrp3 inflammasome activation but limits Th2 type antibody responses. Scientific Reports, 2015, vol. 5, article number 16719. https://doi.org/10.1038/srep16719

58. Seubert A., Calabro S., Santini L., Galli B., Genovese A., Valentini S., Aprea S., Colaprico A., D'Oro U., Giuliani M.M., Pallaoro M., Pizza M., O'Hagan D.T., Wack A., Rappuoli R., De Gregorio E. Adjuvanticity of the oil‐in‐water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proceedings of the National Academy of Sciences, 2011, vol. 108, no. 27, pp. 11169‐11174. https://doi.org/10.1073/pnas.1107941108

59. Fossum C., Hjertner B., Ahlberg V., Charerntantanakul W., McIntosh K., Fuxler L., Balagunaseelan N., Wallgren P., Lövgren Bengtsson K. Early inflammatory response to the saponin adjuvant Matrix‐M in the pig. Veterinary Immunology and Immunopathology, 2014, vol. 158, no. 1‐2, pp. 53‐61. https://doi.org/10.1016/j.vetimm.2013.07.007

60. Filipczak N., Yalamarty S.S.K., Li X., Pathrikar T.V., Pinapati R., Vanjara B., Torchilin V. Neutrophil extracellular traps: Formation, pathological roles, and nanoparticle‐based therapeutic targeting strategies. Journal of Controlled Release, 2025, vol. 387, article number 114220. https://doi.org/10.1016/j.jconrel.2025.114220

61. Gantner B.N., Simmons R.M., Canavera S.J., Akira S., Underhill D.M. Collaborative induction of inflammatory responses by dectin‐ 1 and Toll‐like receptor 2. Journal of Experimental Medicine, 2003, vol. 197, no. 9, pp. 1107‐1117. https://doi.org/10.1084/jem.20021787

62. Verthelyi D., Zeuner R.A. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends in Immunology, 2003, vol. 24, no. 10, pp. 519‐522. https://doi.org/10.1016/s1471‐4906(03)00243‐6

63. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B‐cell activation. Nature, 1995, vol. 374, no. 6522, pp. 546‐549. https://doi.org/10.1038/374546a0

64. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. The Journal of Immunology, 1998, vol. 160, no. 2, pp. 870‐876. https://doi.org/10.4049/jimmunol.160.2.870

65. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., Kielland A., Vosters O., Vanderheyde N., Schiavetti F., Larocque D., Van Mechelen M., Garçon N. AS04, an aluminum salt‐ and TLR4 agonist‐based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. The Journal of Immunology, 2009, vol. 183, no. 10, pp. 6186‐6197. https://doi.org/10.4049/jimmunol.0901474

66. Blanco‐Pérez F., Goretzki A., Wolfheimer S., Schülke S. The vaccine adjuvant MPLA activates glycolytic metabolism in mouse mDC by a JNK‐dependent activation of mTOR‐signaling. Molecular Immunology, 2019, vol. 106, no., pp. 159‐169. https://doi.org/10.1016/j.molimm.2018.12.029

67. Ryan N.M., Hess J.A., Nakhale M., Ferguson A.A., Stump W., Belko S., Monane R., Pugliese R.S., Petrovsky N., Makepeace B.L., Gray S.A., Carter D., Lustigman S., Abraham D. Vaccination against Onchocerca volvulus induces IgG‐mediated protective immunity dependent on neutrophils and complement. NPJ Vaccines, 2025, vol. 10, no. 1, article number 221. https://doi.org/10.1038/s41541‐025‐01267‐x

68. Akin I., Akdas S., Ceylan M.N., Altiner S., Aribal Ayral P., Yazihan N. Evaluation of the safety and efficacy of Advax(TM) as an adjuvant: A systematic review and meta‐analysis. Advances in Medical Sciences, 2022, vol. 67, no. 1, pp. 10‐17. https://doi.org/10.1016/j.advms.2021.09.002

69. Bruchard M., Rebé C., Derangère V., Togbé D., Ryffel B., Boidot R., Humblin E., Hamman A., Chalmin F., Berger H., Chevriaux A., Limagne E., Apetoh L., Végran F., Ghiringhelli F. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nature Immunology, 2015, vol. 16, no. 8, pp. 859‐870. https://doi.org/10.1038/ni.3202

70. Lee W., Kingstad‐Bakke B., Paulson B., Larsen A., Overmyer K., Marinaik C.B., Dulli K., Toy R., Vogel G., Mueller K.P., Tweed K., Walsh A.J., Russell J., Saha K., Reyes L., Skala M.C., Sauer J.D., Shayakhmetov D.M., Coon J., Roy K., Suresh M. Carbomer‐based adjuvant elicits CD8 T‐cell immunity by inducing a distinct metabolic state in cross‐presenting dendritic cells. PLOS Pathogens, 2021, vol. 17, no. 1, article number e1009168. https://doi.org/10.1371/journal.ppat.1009168